Literature DB >> 23319932

Demonstrating the value of biologics: a call to action.

Jeff Clough1.   

Abstract

Efforts to control spending on biologics have been fragmented and inconsistent, and quality information to guide the way is scarce. How can coverage decisions be made without wasting valuable healthcare dollars, while still encouraging new development in therapies?

Year:  2007        PMID： 23319932      PMCID： PMC3541855     

Source DB:  PubMed          Journal:  Biotechnol Healthc        ISSN： 1554-169X


  19 in total

Review 1.  Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.

Authors:  W Clark; J Raftery; F Song; P Barton; C Cummins; A Fry-Smith; A Burls
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

2.  Lucrative niches: how drugs for rare diseases became lifeline for companies.

Authors:  Geeta Anand
Journal:  Wall St J (East Ed)       Date:  2005-11-15

3.  Medicare's coverage of colorectal cancer drugs: a case study in evidence development and policy.

Authors:  Tanisha Carino; Reginald D Williams; Allison M Colbert; Perry Bridger
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

4.  Coverage options for promising technologies: Medicare's 'coverage with evidence development'.

Authors:  Sean R Tunis; Steven D Pearson
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

5.  Newly Final CMS Policy May Help Plans When Evidence For Coverage Is Lacking.

Authors:  Lola Butcher
Journal:  Biotechnol Healthc       Date:  2006-12

6.  The off-label conundrum.

Authors:  Katherine T Adams
Journal:  Biotechnol Healthc       Date:  2006-04

7.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

8.  Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.

Authors:  Angela Zink; Anja Strangfeld; Matthias Schneider; Peter Herzer; Franka Hierse; Maria Stoyanova-Scholz; Siegfried Wassenberg; Andreas Kapelle; Joachim Listing
Journal:  Arthritis Rheum       Date:  2006-11

9.  Management for severe Crohn's disease: a lifetime cost-utility analysis.

Authors:  Isabelle Jaisson-Hot; Bernard Flourié; Louis Descos; Cyrille Colin
Journal:  Int J Technol Assess Health Care       Date:  2004       Impact factor: 2.188

10.  Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

Authors:  R J Pietras; B M Fendly; V R Chazin; M D Pegram; S B Howell; D J Slamon
Journal:  Oncogene       Date:  1994-07       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.